CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novo Nordisk, Inc. v. Viatris Inc.

1:23-cv-00013

Overview

Case Number 1:23-cv-00013
Filing Date 2023-01-27
Status Terminated
Termination Date 2023-11-01
Court District Court, N.D. West Virginia (wvnd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

1 Attorneys Listed

Brandon M. White

Perkins Coie LLP

Tel: +1 (202) 654-6206
Fax: +1 (202) 654-6211

District of Columbia, 700 13th Street NW

Viatris Inc. Operating Company

Represented By

1 Attorneys Listed

Brandon M. White

Perkins Coie LLP

Tel: +1 (202) 654-6206
Fax: +1 (202) 654-6211

District of Columbia, 700 13th Street NW

Plaintiff

Novo Nordisk A/S NPE (Individual / Inventor)

Represented By

10 Attorneys Listed

Scott E. Miller

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 251-7237

565 Fifth Avenue, Suite 2900, New York, NY 10017

Sandra K. Law

Schrader Companion Duff & Law, PLLC

Tel: +1 (304) 233-3390
Fax: +1 (304) 233-2769

401 Main Street, Wheeling, WV 26003

Peter Sandel

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Nicholas Groombridge

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Naz E. Wehrli

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Joshua Reich

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Josephine Young

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0035

565 Fifth Avenue, Suite 2900, New York, NY 10017

Jenny C. Wu

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

James F. Companion

Schrader Companion Duff & Law, PLLC

Tel: +1 (304) 233-3390
Fax: +1 (304) 233-2769

401 Main Street, Wheeling, WV 26003

Daniel J. Klein

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Novo Nordisk, Inc. Operating Company

Represented By

10 Attorneys Listed

Scott E. Miller

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 251-7237

565 Fifth Avenue, Suite 2900, New York, NY 10017

Sandra K. Law

Schrader Companion Duff & Law, PLLC

Tel: +1 (304) 233-3390
Fax: +1 (304) 233-2769

401 Main Street, Wheeling, WV 26003

Peter Sandel

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Nicholas Groombridge

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Naz E. Wehrli

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Joshua Reich

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Josephine Young

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0035

565 Fifth Avenue, Suite 2900, New York, NY 10017

Jenny C. Wu

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

James F. Companion

Schrader Companion Duff & Law, PLLC

Tel: +1 (304) 233-3390
Fax: +1 (304) 233-2769

401 Main Street, Wheeling, WV 26003

Daniel J. Klein

Groombridge, Wu, Baughman & Stone LLP

Tel: +1 (332) 269-0030

565 Fifth Avenue, Suite 2900, New York, NY 10017

Court & Judges

Court

District Court, N.D. West Virginia (wvnd)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 2 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): 🇪🇺 Europe 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (2 found):
PTAB: 2
USPTO PTAB Trial 2023-03-16
IPR2023-00723

Mylan Pharmaceuticals Inc. et al. v. Novo Nordisk A/S

U.S. Continuation Sibling (8129343)
Status: Institution Denied
USPTO PTAB Trial 2023-03-16
IPR2023-00722

Mylan Pharmaceuticals Inc. et al. v. Novo Nordisk A/S

U.S. Continuation Sibling (8536122)
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8129343
Acylated GLP-1 compounds
Filed: 2006-03-20
Issued: 2012-03-06
Active (4.0 yrs remaining) +1722d PTA
Expires: 2030-12-06
US8536122
Acylated GLP-1 compounds
Filed: 2012-03-05
Issued: 2013-09-17
Active (5.3 yrs remaining)
Expires: 2032-03-05
US9764003
Use of long-acting GLP-1 peptides
Filed: 2013-06-21
Issued: 2017-09-19
Active (6.6 yrs remaining)
Expires: 2033-06-21
US10888605
GLP-1 compositions and uses thereof
Filed: 2020-01-28
Issued: 2021-01-12
Active (13.2 yrs remaining)
Expires: 2040-01-28
US11318191
GLP-1 compositions and uses thereof
Filed: 2021-02-17
Issued: 2022-05-03
Active (14.2 yrs remaining)
Expires: 2041-02-17

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1722 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

21

Dispositive

0

Granted

0

Denied

1

Pending / Review

20

Motions by Category

Procedural / Extension Motion 21

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
Joint MOTION for Extension of Time to File Joint Planning Report by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Proposed Order)(White, Brandon) ...
Entry #36 • 2023-06-14 Document →
Procedural / Extension Motion Denied
ORDER DENYING JOINT MOTION FOR EXTENSION [ECF No. 33 ]. Signed by Chief District Judge Thomas S Kleeh on 6/5/2023. (hrc) (Entered: 06/05/2023)
Entry #34 • 2023-06-05 Document →
Procedural / Extension Motion Pending / Under Review
Joint MOTION for Extension of Time to File Joint Report of Initial Planning Meeting by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Proposed Orde...
Entry #33 • 2023-06-01 Document →
Procedural / Extension Motion Pending / Under Review
Joint MOTION for Extension of Time to File Joint Report of Initial Planning Meeting by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Proposed Orde...
Entry #31 • 2023-05-17 Document →
Procedural / Extension Motion Pending / Under Review
Joint MOTION for Extension to hold Initial Planning Meeting and to submit Joint Report of Initial Planning Meeting by Novo Nordisk A/S, Novo Nordisk, Inc.. (Att...
Entry #29 • 2023-05-03 Document →
Procedural / Extension Motion Pending / Under Review
ORDER: Granting 6 Motion for Leave to Appear Pro Hac Vice of Nicholas Groombridge. Signed by Chief District Judge Thomas S Kleeh on 2/17/2023. (hrc) (Entered: 0...
Entry #16 • 2023-02-17 Document →

Docket Entries

(42 total)
Pleading / Complaint

COMPLAINT against Mylan Pharmaceuticals Inc., Viatris Inc., filed by Novo Nordisk, Inc., Novo Nordisk A/S. Filing Fee Paid $402. Receipt #AWVNDC-3636472. (Attachments: # 1 Exhibit 1 - Patent No. US 8,129,343 B2, # 2 Exhibit 2 - Patent No. US 8,536,122 B2, # 3 Exhibit 3 - Patent No. US 9,764,003 B2, # 4 Exhibit 4 - Patent No. US 10,888,605 B2, # 5 Exhibit 5 - Patent No. US 11,318,191 B2, # 6 Civil Cover Sheet)(dk) (Entered: 01/30/2023)

Entry #1 • 2023-01-27
1

SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA) filed by Novo Nordisk A/S, Novo Nordisk, Inc. (dk) (Entered: 01/30/2023)

Entry #2 • 2023-01-27
1

PLAINTIFFS' FED.R.CIV.P. 7.1 STATEMENT by Novo Nordisk A/S, Novo Nordisk, Inc. (dk) (Entered: 01/30/2023)

Entry #3 • 2023-01-27
1
Pleading / Complaint

REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (dk) (Entered: 01/30/2023)

Entry #4 • 2023-01-30
1

VERIFICATION OF ATTORNEY ADMISSION to Attorneys N. Groombridge, P. Sandel, D. Klein, J. Wu, J. Reich, N. Wehrli, and J. Young. (dk) (Entered: 01/30/2023)

Entry #5 • 2023-01-30
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc